Table 2.
Incidence of subjects positive for immunoglobulin G antibodies, in adenovirus, cytomegalovirus, Epstein-Barr virus, and varicella-zoster virus in the Umeå, Malmö, and Copenhagen cohorts
| All subjects | Controls | Glioma cases | Glioblastoma Sweden | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. positive/total no. | Positive (%) | No. positive/total no. | Positive (%) | No. positive/total no. | % positive | p-value | No. positive/total no. | % positive | p-valuea | |
| Immunoglobulin G antibodies | ||||||||||
| Adenovirus | 584/589 | 99.2 | 388/393 | 98.7 | 196/196 | 100 | 0.18 | 61/61 | 100 | 1.00 |
| Cytomegalovirus | 504/589 | 85.6 | 335/393 | 85.2 | 169/196 | 86.2 | 0.80 | 53/61 | 86.9 | 1.00 |
| Epstein-Barr virus | 511/587 | 87.1 | 347/391 | 88.7 | 164/196 | 83.7 | 0.09 | 54/61 | 88.5 | 0.15 |
| Varicella-zoster virus | 582/589 | 98.8 | 389/393 | 99.0 | 193/196 | 98.5 | 0.69 | 59/61 | 96.7 | 0.26 |
Cases/controls and Swedish cases (Umeå and Malmö) with glioblastoma shown separately. Information on tumor subtypes was not available for the cases from Copenhagen. No significant difference in numbers positive between cases and controls
aControls from Copenhagen excluded in the analysis